Collagenase Clostridium histolyticum in the treatment of Peyronie’s disease: patient selection and perspectives

References

• DibenedettiDBNyugenDZografosLZhouXA population-based study of Peyronie’s disease: prevalence and treatment patterns in the United StatesAdv Urol2011201128250328250922110491
   PubMedGoogle Scholar
• TaylorFLLevineLAPeyronie’s diseaseUrol Clin North Am20073451753417983892
   PubMed Web of Science ®Google Scholar
• MulhallJPCreechSDBoorjianSASubjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screeningJ Urol20041712350235315126819
   PubMed Web of Science ®Google Scholar
• PoullisCShabbirMEardleyIMulhallJMinhasSClostridium histolyticum collagenase – is this a revolutionary medical treatment for Peyronie’s disease?BJU Int201611818618926683137
   PubMed Web of Science ®Google Scholar
• MulhallJPSchiffJGuhringPAn analysis of the natural history of Peyronie’s diseaseJ Urol200617562115211816697815
   PubMed Web of Science ®Google Scholar
• KadiogluATefekliAErolBOktarTTuncMTellalogluSA retrospective review of 307 men with Peyronie’s diseaseJ Urol20021681075107912187226
   PubMed Web of Science ®Google Scholar
• KelamiAClassification of congenital and acquired penile deviationUrol Int1983382296879869
   PubMed Web of Science ®Google Scholar
• GelbardMHellstromWJMcMahonCGBaseline characteristics from an ongoing Phase 3 study of collagenase Clostridium histolyticum in patients with Peyronie’s diseaseJ Sex Med2013102822283124112401
   PubMed Web of Science ®Google Scholar
• SerefogluEBerktasMYafiFRelationship of factors associated with Peyronie’s disease that affect PD bother and erectile dysfunctionJ Urol2015193E970
   Web of Science ®Google Scholar
• SmithJFWalshTJContiSLTurekPLueTRisk factors for emotional and relationship problems in Peyronie’s diseaseJ Sex Med200852179218418638001
   PubMed Web of Science ®Google Scholar
• NelsonCJDiblasioCKendirciMHellstromWGuhringPMulhallJPThe chronology of depression and distress in men with Peyronie’s diseaseJ Sex Med200851985199018554257
   PubMed Web of Science ®Google Scholar
• HellstromWJBivalacquaTJPeyronie’s disease: etiology, medical, and surgical therapyJ Androl20002134710819440
   PubMed Web of Science ®Google Scholar
• NehraAAlterowitzRCulkinDJPeyronie’s disease: AUA GuidelineJ Urol2015194374575326066402
   PubMed Web of Science ®Google Scholar
• CarsonCCSadeghi-NejadHTursiJPAnalysis of the clinical safety of intralesional injection of collagenase Clostridium histolyticum (CCH) for adults with Peyronie’s disease (PD)BJU Int201511681582225818264
   PubMed Web of Science ®Google Scholar
• HellstromWJFeldmanRRosenRCSmithTKaufmanGTursiJBother and distress associated with Peyronie’s disease: validation of the Peyronie’s disease questionnaireJ Urol201319062763423376705
   PubMed Web of Science ®Google Scholar
• GelbardMGoldsteinIHellstromWJClinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studiesJ Urol201319019920723376148
   PubMed Web of Science ®Google Scholar
• LevineLACuzinBMarkSClinical safety and effectiveness of collagenase Clostridium histolyticum injection in patients with Peyronie’s disease: a phase 3 open-label studyJ Sex Med20151224825825388099
   PubMed Web of Science ®Google Scholar
• LevineLALarsenSMSurgical correction of persistent Peyronie’s disease following collagenase Clostridium histolyticum treatmentJ Sex Med20151225926425345351
   PubMed Web of Science ®Google Scholar
• BreyerBNShindelAWHuangYAre sonographic characteristics associated with progression to surgery in men with Peyronie’s disease?J Urol20101831484148820171694
   PubMed Web of Science ®Google Scholar
• YafiFAHatzichristodoulouGDeLayKJHellstromWJReview of management options for patients with atypical Peyronie’s diseaseSex Med Rev2016 piiS2050-0521(16):30030-0. [Epub ahead of print]
   Web of Science ®Google Scholar
• Xiaflex^® (Collagenase Clostridium histolyticum) [prescribing information]MalvernAuxilium Pharmaceuticals, Inc.2014142
   Google Scholar
• LipshultzLIGoldsteinISeftelADClinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie’s disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studiesBJU Int201511665065625711400
   PubMed Web of Science ®Google Scholar
• GelbardMKJamesKRiachPDoreyFCollagenase versus placebo in the treatment of Peyronie’s disease: a double-blind studyJ Urol1993149568417217
   PubMed Web of Science ®Google Scholar
• GoldsteinIKarshLMillsJ1656 Clinical evaluation of treatment of Peyronie’s disease with collagenase Clostridium histolyticum: analysis of penile curvature deformity by duration of disease and plaque calcificationJ Urol20131894e681e682
   Web of Science ®Google Scholar
• LevineLAGelbardMKTursiJPPD48-06 outcomes associated with collagenase Clostridium histolyticum for Peyronie’s disease by duration of diseaseJ Urol2015193e968
   Web of Science ®Google Scholar
• YangKKBennettNPeyronie’s disease and injectable collagenase Clostridium histolyticum: safety, efficacy, and improvements in subjective symptomsUrol20169414314727211926
   PubMed Web of Science ®Google Scholar
• RybakJHehemannMCorderCLevineL1695 Does calcification of Peyronie’s disease plaque predict progression to surgical intervention?J Urol2012187e684
   Web of Science ®Google Scholar
• ChungEDe YoungLBrockGBPenile duplex ultrasonography in men with Peyronie’s disease: is it veno-occlusive dysfunction or poor cavernosal arterial inflow that contributes to erectile dysfunction?J Sex Med201183446345121981553
   PubMed Web of Science ®Google Scholar
• HertzmanBLiuGTursiJHobsonSKaminetskyJ1657 Subgroup analysis of curvature deformity severity and symptom bother improvement in patients with Peyronie’s disease being treated with collagenase Clostridium histolyticum in clinical studiesJ Urol20131894e682
   Web of Science ®Google Scholar
• AnaissieJYafiFATraoreEJSikkaSCHellstromWJPD45-02 Impact of number of cycles of collagenase Clostridium histolyticum on outcomes in patients with Peyronie’s diseaseJ Urol2016195e1061
   Web of Science ®Google Scholar
• GoldsteinIKnollDLipshultzLIMcmahonCGPD48-07 changes in the effects of Peyronie’s disease after treatment with collagenase Clostridium histolyticum according to men with Peyronie’s disease and their female sexual partnersJ Urol2015193e968e969
   Web of Science ®Google Scholar
• GelbardMLipshultzLITursiJSmithTKaufmanGLevineLAPhase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie diseaseJ Urol201218762268227422503048
   PubMed Web of Science ®Google Scholar
• YafiFAHatzichristodoulouGKnoedlerCJTrostLWSikkaSCHellstromWJComparative analysis of tunical plication vs. intralesional injection therapy for ventral Peyronie’s diseaseJ Sex Med2015122492249826646187
   PubMed Web of Science ®Google Scholar
• StewartCYafiFKnoedlerMIntralesional injection of interferon-alpha 2b improves penile curvature in men with Peyronie’s disease independent of plaque locationJ Urol20151941704170726144333
   PubMed Web of Science ®Google Scholar
• SangkumPYafiFKimHCollagenase Clostridium histolyticum (Xiaflex) for the treatment of urethral stricture disease in a rat model of urethral fibrosisUrol201586647.e1e626126692
   PubMed Web of Science ®Google Scholar
• MilamD116 Positive results with collagenase Clostridium histolyticum treatment in two patients with ventral penile curvature due to Peyronie’s diseaseJ Sex Med2016135S55
   Web of Science ®Google Scholar
• CakanMAkmanTOktarTGurkanLCeltikMKadiogluAThe clinical characteristics of Peyronie’s patients with notching deformityJ Sex Med200741174117817662024
   PubMed Web of Science ®Google Scholar
• PeimerCABlazarPColemanSDupuytren contracture recurrence following treatment with collagenase Clostridium histolyticum (CORDLESS study): 3-year dataJ Hand Surg Am201338122223200951
   PubMed Web of Science ®Google Scholar
• TraoreEJYafiFAAnaissieJSikkaSCHellstromWJGPD45-03 survey of patient and partner satisfaction following collagenase Clostridium histolyticum treatment for Peyronie’s diseaseJ Urol20161954e1061e1062
   Web of Science ®Google Scholar
• HellstromWJGittlemanMTanRBPD22-02 meaningful change in Peyronie’s disease following treatment with collagenase Clostridium histolyticum: results from two large double-blind, randomized, placebo-controlled phase 3 studiesJ Urol2014191e672
   Web of Science ®Google Scholar
• ZiegelmannMJViersBRMcAlvanyKLRestoration of penile function and patient satisfaction with intralesional collagenase Clostridium histolyticum injection for Peyronie’s diseaseJ Urol2016195105126476353
   PubMed Web of Science ®Google Scholar
• CoyneKSCurrieBMThompsonCLSmithTMResponsiveness of the Peyronie’s Disease Questionnaire (PDQ)J Sex Med2015121072107925664497
   PubMed Web of Science ®Google Scholar
• CordonBHutchinsonRHoferMBroderickGLotanYMoreyAPD45-06 superior cost effectiveness of penile plication versus intralesional collagenase injection for treatment of Peyronie’s disease deformitiesJ Urol2016195e1062e1063
   Web of Science ®Google Scholar
• TerrierJENelsonCJPsychological aspects of Peyronie’s diseaseTransl Androl Urol2016529027298775
   PubMed Web of Science ®Google Scholar